EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparative efficacy of systemic therapies in malignant insulinoma

Regina Koch iD, Patrick Walsh McGarrah, Adrian Vella, Pankaj Shah, Timothy J Hobday, Mohamed Bassam Sonbol, Jason Starr iD, Rachel Eiring, Travis J McKenzie, Alaa Sada, Patrick Starlinger, Hallbera Gudmundsdottir iD und 1 weitere

Endocrine-Related Cancer · 01.06.2025 · 32 (6)

DOI: 10.1530/erc-25-0091 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Endocrine-Related Cancer, online erschienen am 29.05.2025. Verfasst von Regina Koch und 12 weiteren Autor:innen. Hauptthemen laut MEDLINE: Insulinoma, Pancreatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Malignant insulinomas are rare pancreatic neuroendocrine tumors characterized by excessive insulin secretion and a high propensity for metastasis, leading to challenging management. This study retrospectively analyzed 57 patients treated for malignant insulinoma at Mayo Clinic sites between 1992 and 2024, focusing on the efficacy of systemic therapies in improving hypoglycemic control and survival outcomes. The most commonly used therapies included somatostatin analogs (SSA), everolimus, capecitabine-temozolomide (CAPTEM), and peptide receptor radionuclide therapy (PRRT). PRRT demonstrated the highest efficacy in controlling hypoglycemia (93%), followed by CAPTEM (68%) and everolimus (62%). SSA, chemotherapy, and streptozocin were less effective, with hypoglycemic improvement seen in 37.5, 33.3, and 28.6% of patients, respectively. Overall survival (OS) was longest with SSA at 84.67 months, followed by CAPTEM at 81.67 months and everolimus at 74.07 months. PRRT demonstrated a median OS of 49.73 months. In contrast, chemotherapy and streptozocin-based therapies had significantly shorter OS times of 15.23 and 8.35 months, respectively. These findings highlight significant variability in systemic therapy efficacy for malignant insulinoma, with PRRT emerging as a promising treatment for refractory hypoglycemia and long survival. Cox regression analysis identified primary tumor resection and a history of benign insulinoma as associated with longer OS. Optimal sequencing of therapies remains unclear, and individualized treatment plans based on hypoglycemic burden and tumor characteristics are critical for improving survival and quality of life in these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InsulinomaPancreatic NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedRetrospective StudiesAdultAgedTreatment Outcome

Stichwörter der Autor:innen

chemotherapyinsulinomasmetastasisneuroendocrine tumorsoncology

Autor:innen und Institutionen

ORCID-Profile: Regina Koch, Jason Starr, Hallbera Gudmundsdottir

Zitieren

APA

Koch, R., McGarrah, P. W., Vella, A., Shah, P., Hobday, T. J., Sonbol, M. B., Starr, J., Eiring, R., McKenzie, T. J., Sada, A., Starlinger, P., Gudmundsdottir, H., & Halfdanarson, T. R. (2025). Comparative efficacy of systemic therapies in malignant insulinoma. Endocrine-Related Cancer, 32(6). https://doi.org/10.1530/erc-25-0091

Vancouver

Koch R, McGarrah PW, Vella A, Shah P, Hobday TJ, Sonbol MB, et al. Comparative efficacy of systemic therapies in malignant insulinoma. Endocrine-Related Cancer. 2025;32(6). doi:10.1530/erc-25-0091

BibTeX
@article{Koch2025,
  author = {Koch, Regina and McGarrah, Patrick Walsh and Vella, Adrian and Shah, Pankaj and Hobday, Timothy J and Sonbol, Mohamed Bassam and Starr, Jason and Eiring, Rachel and McKenzie, Travis J and Sada, Alaa and Starlinger, Patrick and Gudmundsdottir, Hallbera and Halfdanarson, Thorvadur R},
  title = {Comparative efficacy of systemic therapies in malignant insulinoma},
  journal = {Endocrine-Related Cancer},
  year = {2025},
  volume = {32},
  number = {6},
  doi = {10.1530/erc-25-0091}
}
Kostenlos starten →